Takeda Pharmaceutical Company Limited
TAK
$15.91
$0.261.66%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -0.95% | -1.29% | -2.14% | 1.39% | 1.81% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -0.95% | -1.29% | -2.14% | 1.39% | 1.81% |
| Cost of Revenue | 3.52% | -1.77% | 1.04% | 4.56% | 4.24% |
| Gross Profit | -3.28% | -1.04% | -3.78% | -0.24% | 0.59% |
| SG&A Expenses | -1.37% | 0.47% | -0.89% | 1.04% | -0.55% |
| Depreciation & Amortization | -7.73% | -1.08% | 79.11% | -0.89% | -1.29% |
| Other Operating Expenses | -54.42% | -88.81% | 391.39% | -70.57% | 84.81% |
| Total Operating Expenses | -2.37% | -1.73% | 8.60% | 0.11% | 1.05% |
| Operating Income | 9.20% | 1.58% | -45.34% | 11.28% | 7.55% |
| Income Before Tax | -164.92% | -8.75% | -60.38% | 328.54% | 177.19% |
| Income Tax Expenses | -75.70% | 275.59% | 389.12% | 153.11% | 172.80% |
| Earnings from Continuing Operations | -219.86% | -43.13% | -86.47% | -1.61% | -30.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -22.81% | -43.34% | -24.35% | -17.00% | -58.04% |
| Net Income | -220.35% | -43.21% | -86.54% | -1.63% | -30.09% |
| EBIT | 9.20% | 1.58% | -45.34% | 11.28% | 7.55% |
| EBITDA | -9.01% | 21.59% | -1.30% | 38.82% | 36.43% |
| EPS Basic | -218.53% | -42.60% | -86.16% | -1.48% | -30.61% |
| Normalized Basic EPS | 11.93% | 14.76% | -53.55% | 14.33% | 12.77% |
| EPS Diluted | -225.06% | -43.64% | -86.70% | -3.07% | -32.06% |
| Normalized Diluted EPS | 12.34% | 15.18% | -53.54% | 13.40% | 11.67% |
| Average Basic Shares Outstanding | -0.28% | -0.04% | 0.32% | 0.69% | 0.99% |
| Average Diluted Shares Outstanding | -0.22% | 0.01% | -0.06% | 1.17% | 1.57% |
| Dividend Per Share | 0.13% | 2.22% | 2.22% | 1.44% | 1.44% |
| Payout Ratio | -1.88% | 0.88% | 6.95% | 0.09% | 0.40% |